KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) Interest Expenses (2016 - 2026)

Boston Scientific's Interest Expenses history spans 18 years, with the latest figure at $90.0 million for Q1 2026.

  • On a quarterly basis, Interest Expenses rose 9.76% to $90.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $357.0 million, a 12.26% increase, with the full-year FY2025 number at $349.0 million, up 14.43% from a year prior.
  • Interest Expenses hit $90.0 million in Q1 2026 for Boston Scientific, roughly flat from $90.0 million in the prior quarter.
  • Over the last five years, Interest Expenses for BSX hit a ceiling of $279.0 million in Q1 2022 and a floor of $63.0 million in Q3 2022.
  • Historically, Interest Expenses has averaged $87.1 million across 5 years, with a median of $77.0 million in 2024.
  • Biggest five-year swings in Interest Expenses: skyrocketed 240.24% in 2022 and later tumbled 76.7% in 2023.
  • Tracing BSX's Interest Expenses over 5 years: stood at $64.0 million in 2022, then increased by 1.56% to $65.0 million in 2023, then grew by 23.08% to $80.0 million in 2024, then grew by 12.5% to $90.0 million in 2025, then changed by 0.0% to $90.0 million in 2026.
  • Business Quant data shows Interest Expenses for BSX at $90.0 million in Q1 2026, $90.0 million in Q4 2025, and $87.0 million in Q3 2025.